Landos Biopharma to participate in CEO of Truist Securities


BLACKSBURG, Va., September 27, 2021 (GLOBE NEWSWIRE) – Landos Biopharma, Inc. (NASDAQ: LABP), an advanced clinical stage biopharmaceutical company using its LANCE® advanced AI platform to develop new therapies for patients with autoimmune diseases, announced today that Josep Bassaganya-Riera, Chairman of the Board, President and CEO of Landos, will participate in the series Fireside Chat from Truist Securities (Virtual). The event will feature a one-on-one conversation led by Robyn Karnauskas, Ph.D., Managing Director and Senior Biotechnology Analyst, with audience participation, discussing all aspects of Landos Biopharma. Investors interested in participating should contact their Truist Securities representative or, Marek Ciszewski, [email protected]

Event: Truist Securities CEO Fireside Conversation Series (Virtual)
Dated: September 30, 2021
Time: 10:00 a.m.ET to 11:00 a.m.ET

About Landos Biopharma
Landos Biopharma is an advanced stage biopharmaceutical company using its LANCE® Advanced AI platform to discover and develop new therapies for patients with autoimmune diseases. Using the LANCE® platform, the Company has discovered new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma has 17 active development programs targeting these new pathways at the interface of immunity and metabolism. Its lead product candidate, omilancor, targets the LANCL2 pathway and is a novel, potentially first-in-class, oral, gut-restricted therapeutic molecule currently in preparation for global phase 3 pivotal trials for the treatment of ulcerative colitis, in two Phase 2 trials in Crohn’s disease, and is expected to initiate Phase 1 studies in eosinophilic esophagitis in 2022. Omilancor is also being investigated in a topical formulation for psoriasis and atopic dermatitis. Landos has another new oral restricted small molecule drug candidate, NX-13, which is being investigated in an active Phase 1b trial in ulcerative colitis. NX-13 targets the NLRX1 pathway. Landos’ sixth new product candidate, LABP-104, will enter Phase 1 clinical trials in healthy volunteers in the fourth quarter of 2021. Other product candidates are under development for the treatment of lupus nephritis, Rheumatoid arthritis, multiple sclerosis, Alzheimer’s disease, alcoholic steatohepatitis (NASH), asthma, chronic obstructive pulmonary disease (COPD), diabetes and diabetic nephropathy. For more information, please visit

Marek Ciszewski, JD
Landos Biopharma
[email protected]

Michael K. Levitan (investors)
Solebury Trout
[email protected]

Hannah Gendel (media)
Solebury Trout
[email protected]


Previous Hit K-drama 'Squid Game' accused of plagiarizing Japanese film 'As The Gods Will'
Next Henry Rollins joins the cast of the animated sci-fi series "NEW-GEN"

No Comment

Leave a reply

Your email address will not be published.